Free tools, free alerts. Create a free account to get sector-matched alerts and save your searches.
Create free account →
NAFDAC has intensified enforcement against counterfeit pharmaceuticals and regulatory non-compliance, including blacklisting a manufacturer and issuing public alerts. These actions signal a stricter regulatory environment for pharmaceutical and medical device businesses, requiring enhanced due diligence and compliance measures.
Pharmaceuticals
Medical Devices
Food and Beverages
Export/Import
Healthcare
NAFDAC joins the Federal Ministry of Health and Social Welfare, nutrition partners, and the global community in celebrating World Breastfeeding Week 2026
NAFDAC
NAFDAC celebrates World Breastfeeding Week 2026, promoting breastfeeding awareness and support.
Encourages SMBs in nutrition and healthcare to align with breastfeeding advocacy; potential for partnerships and compliance with nutrition labeling standards.
Handling Manufacturer Investigation Reports for Medical Devices and IVDs
NAFDAC
NAFDAC provides guidance on handling Manufacturer Investigation Reports (MIRs) for medical devices and IVDs to ensure safety and quality.
Medical device and IVD SMBs must implement robust complaint and adverse event reporting processes to comply with NAFDAC expectations.
Blacklisting of Onifam Laboratories Ltd
NAFDAC
NAFDAC blacklists Onifam Laboratories Ltd and associated entities from pharmaceutical business activities due to regulatory misrepresentation and improper use of approvals.
SMBs in pharmaceutical distribution must verify partners' compliance records to avoid association with blacklisted entities; reinforces need for transparent regulatory practices.
Public Alert No. 037/2026 – Alert on Suspected Counterfeit Pulmicort® (Budesonide) Inhalation Suspension
NAFDAC
NAFDAC alerts the public to suspected counterfeit Pulmicort® (Budesonide) inhalation suspension in the market.
Pharmacies and distributors must verify product authenticity and report suspected counterfeits to NAFDAC; heightened vigilance required.
Public Alert No. 036/2026 – Alert on Suspected Counterfeit Products Mimicking Forxiga® (Dapagliflozin)
NAFDAC
NAFDAC alerts the public to suspected counterfeit Forxiga® (dapagliflozin) products in the Nigerian market.
SMBs in pharmaceutical supply chain must ensure traceability and authenticity of products to avoid legal and safety issues.
SON rides on e-platform to facilitate international trade - Business News Nigeria
Other
SON leverages an electronic platform to streamline international trade processes.
SMBs involved in import/export should utilize SON's e-platform for faster and more transparent trade facilitation.
How to Register Your Fish Farm with NEPC Nigeria: A Complete Export Guide - within nigeria
Other
Guide on registering fish farms with NEPC for export purposes.
Fish farming SMBs can access export opportunities by registering with NEPC, expanding market reach.
Increased enforcement against counterfeit drugs and regulatory non-compliance.
Need for robust quality assurance and traceability in pharmaceutical supply chains.
Opportunities for SMBs in nutrition and healthcare to align with public health campaigns.
Digital platforms (SON e-platform) can simplify trade processes.
Export opportunities in agriculture (fish farming) with proper registration.
1
Verify all pharmaceutical products for authenticity and report suspected counterfeits to NAFDAC.
2
Conduct due diligence on business partners to avoid associations with blacklisted entities.
3
Implement robust complaint and adverse event reporting systems for medical devices and IVDs.
4
Leverage SON's e-platform for import/export documentation.
5
Register fish farms with NEPC to explore export markets.
6
Stay updated on NAFDAC alerts and guidelines to ensure compliance.